MA52212A - Anticorps multivalent - Google Patents

Anticorps multivalent

Info

Publication number
MA52212A
MA52212A MA052212A MA52212A MA52212A MA 52212 A MA52212 A MA 52212A MA 052212 A MA052212 A MA 052212A MA 52212 A MA52212 A MA 52212A MA 52212 A MA52212 A MA 52212A
Authority
MA
Morocco
Prior art keywords
multivalent antibody
multivalent
antibody
Prior art date
Application number
MA052212A
Other languages
English (en)
Inventor
Kruif Cornelis Adriaan De
Linda Johanna Aleida Hendriks
Ton Logtenberg
Loo Pieter Fokko Van
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MA52212A publication Critical patent/MA52212A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA052212A 2018-03-30 2019-03-29 Anticorps multivalent MA52212A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862650467P 2018-03-30 2018-03-30

Publications (1)

Publication Number Publication Date
MA52212A true MA52212A (fr) 2021-02-17

Family

ID=66349617

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052212A MA52212A (fr) 2018-03-30 2019-03-29 Anticorps multivalent

Country Status (18)

Country Link
US (3) US11952424B2 (fr)
EP (1) EP3774885A2 (fr)
JP (2) JP7603578B2 (fr)
KR (1) KR20200139189A (fr)
CN (1) CN111936514A (fr)
AR (1) AR115320A1 (fr)
AU (2) AU2019243665B2 (fr)
BR (1) BR112020019795A2 (fr)
CA (1) CA3094318A1 (fr)
EA (1) EA202091871A1 (fr)
IL (1) IL277672A (fr)
MA (1) MA52212A (fr)
MX (1) MX2020010267A (fr)
NZ (1) NZ767923A (fr)
PH (1) PH12020551504A1 (fr)
SG (1) SG11202009036YA (fr)
TW (1) TW202003569A (fr)
WO (1) WO2019190327A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52212A (fr) 2018-03-30 2021-02-17 Merus Nv Anticorps multivalent
JP7443376B2 (ja) 2018-12-31 2024-03-05 メルス ナムローゼ フェンノートシャップ 混合結合ドメイン
CN113439089A (zh) 2018-12-31 2021-09-24 美勒斯公司 截短的多价多元体
CN114605546A (zh) * 2019-03-29 2022-06-10 美勒斯公司 Cd3结合分子
TW202546002A (zh) * 2019-03-29 2025-12-01 荷蘭商美勒斯公司 Cd3結合分子
CA3139402A1 (fr) 2019-05-09 2020-11-12 Merus N.V. Domaines variants pour la multimerisation de proteines et leur separation
AU2020412201B2 (en) 2019-12-24 2026-02-12 Merus B.V. TGF-beta-RII binding proteins
US20230210988A1 (en) * 2020-01-29 2023-07-06 Merus N.V. Means and method for modulating immune cell engaging effects
US20230151115A1 (en) * 2020-03-31 2023-05-18 University Public Corporation Osaka Multispecific antibody and method for producing same
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2021226984A1 (fr) 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 Anticorps bispécifique tétravalent contre pd-1 et pd-l1
CA3175227A1 (fr) 2020-05-21 2021-11-25 Cornelis De Kruif Procedes et moyens pour la production de molecules de type ig
EP4244382A1 (fr) * 2020-11-11 2023-09-20 Nautilus Subsidiary, Inc. Réactifs d'affinité ayant des caractéristiques de liaison et de détection améliorées
CN115536749A (zh) * 2021-06-29 2022-12-30 三生国健药业（上海）股份有限公司 三特异性抗体、其制备方法和用途
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
AU2023228391A1 (en) * 2022-03-03 2024-09-19 Pfizer Inc. Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
US20230383012A1 (en) * 2022-04-13 2023-11-30 Xencor, Inc. Antibodies that bind pd-l1, pd-l2, and/or cd28
CN120641444A (zh) 2022-12-27 2025-09-12 美勒斯公司 产生双重特异性蛋白的方法
WO2024144400A1 (fr) * 2022-12-30 2024-07-04 Merus N.V. Molécules de liaison à cd3 ubiquistes
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2024206568A2 (fr) * 2023-03-31 2024-10-03 Ibio, Inc. Anticorps anti-cd3
WO2025230409A1 (fr) 2024-04-30 2025-11-06 Merus N.V. Conjugués anticorps-médicament multispécifiques
WO2025230410A1 (fr) 2024-04-30 2025-11-06 Merus N.V. Conjugués anticorps-médicament multispécifiques
WO2026013015A1 (fr) * 2024-07-09 2026-01-15 Merus N.V. Fractions de liaison multispécifiques comprenant des domaines de liaison à calr et cd3
WO2026018064A1 (fr) 2024-07-16 2026-01-22 Merus N.V. Conjugués anticorps-médicament multi-médicament multispécifiques

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
ATE545703T1 (de) * 2000-07-25 2012-03-15 Immunomedics Inc Multivalentes zielbindendes protein
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PT3456190T (pt) 2008-06-27 2022-02-15 Merus Nv Animal murino transgénico produtor de anticorpo
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
AU2010249470B2 (en) 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
EP2435473B1 (fr) * 2009-05-27 2013-10-02 F.Hoffmann-La Roche Ag Anticorps tri ou tétra-spécifiques
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
EP2513312B1 (fr) 2009-12-17 2015-03-18 NovImmune SA Bibliothèques de polypeptides synthétiques et procédés de production de variants polypeptidiques naturellement diversifiés
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
MX2014002289A (es) * 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
HRP20181717T1 (hr) 2012-09-27 2018-12-28 Merus N.V. Bispecifična igg protutijela kao aktivatori t stanice
ES2667420T3 (es) 2013-02-05 2018-05-10 Engmab Sàrl Anticuerpos biespecíficos contra cd3epsilon y bcma
WO2014131711A1 (fr) 2013-02-26 2014-09-04 Roche Glycart Ag Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
EP2789630A1 (fr) 2013-04-09 2014-10-15 EngMab AG Anticorps bispécifiques contre le CD3e et ROR1
NZ720353A (en) * 2013-12-30 2019-12-20 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
HRP20250041T1 (hr) 2014-02-28 2025-03-14 Merus N.V. Antitijelo koje veže erbb-2 i erbb-3
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
TWI742423B (zh) 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
EP2982692A1 (fr) 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
US20170306044A1 (en) 2014-10-09 2017-10-26 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
EP3023437A1 (fr) 2014-11-20 2016-05-25 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
EP3237449A2 (fr) 2014-12-22 2017-11-01 Xencor, Inc. Anticorps trispécifiques
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
ES2693596T3 (es) * 2015-07-10 2018-12-12 Merus N.V. Anticuerpo que se une a CD3 humano
EP3670535A1 (fr) 2015-08-03 2020-06-24 EngMab Sàrl Anticorps monoclonaux contre bcma
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
KR20250157457A (ko) * 2015-10-23 2025-11-04 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
PT3998285T (pt) 2016-03-25 2025-04-14 Biomunex Pharmaceuticals Moléculas de ligação a cd38 e pd-l1
PE20181952A1 (es) * 2016-04-27 2018-12-17 Pfizer Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
RU2018141777A (ru) 2016-04-28 2020-05-28 Биомюнё Фармасьютикалз Биспецифичные антитела, нацеленные на egfr и her2
WO2018014260A1 (fr) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
KR102617264B1 (ko) 2016-10-19 2023-12-29 인벤라 인코포레이티드 항체 구조물
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
WO2018182422A1 (fr) * 2017-03-31 2018-10-04 Merus N.V. Anticorps bispécifiques de liaison à l'erbb-2 et erbb-3 destinés à être utilisés dans le traitement des cellules (f) qui présentent un gène de fusion (nrg1)
EP3600411A1 (fr) * 2017-03-31 2020-02-05 Merus N.V. Anticorps pour le traitement de tumeurs positives erbb-2/erbb-3
TW202542197A (zh) * 2017-07-06 2025-11-01 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
IL271832B2 (en) * 2017-07-06 2025-07-01 Merus Nv Bispecific anti pd1-anti tim3 antibodies and uses thereof
EA202090003A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
PL3665198T3 (pl) * 2017-08-09 2025-06-09 Merus N.V. Przeciwciała wiążące egfr i cmet
US20200384084A1 (en) * 2017-12-01 2020-12-10 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
MA52212A (fr) 2018-03-30 2021-02-17 Merus Nv Anticorps multivalent
JP7443376B2 (ja) * 2018-12-31 2024-03-05 メルス ナムローゼ フェンノートシャップ 混合結合ドメイン
CA3139402A1 (fr) * 2019-05-09 2020-11-12 Merus N.V. Domaines variants pour la multimerisation de proteines et leur separation
CN114761037A (zh) * 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
US20230210988A1 (en) * 2020-01-29 2023-07-06 Merus N.V. Means and method for modulating immune cell engaging effects

Also Published As

Publication number Publication date
EA202091871A1 (ru) 2021-06-22
JP2024161509A (ja) 2024-11-19
US20240352127A1 (en) 2024-10-24
WO2019190327A3 (fr) 2019-11-14
SG11202009036YA (en) 2020-10-29
BR112020019795A2 (pt) 2021-01-05
JP7603578B2 (ja) 2024-12-20
WO2019190327A8 (fr) 2021-06-17
TW202003569A (zh) 2020-01-16
US20240360217A1 (en) 2024-10-31
IL277672A (en) 2020-11-30
AU2019243665A1 (en) 2020-10-08
WO2019190327A2 (fr) 2019-10-03
NZ767923A (en) 2024-11-29
KR20200139189A (ko) 2020-12-11
CA3094318A1 (fr) 2019-10-03
PH12020551504A1 (en) 2021-09-13
AU2019243665B2 (en) 2023-06-01
US20190352401A1 (en) 2019-11-21
US11952424B2 (en) 2024-04-09
MX2020010267A (es) 2020-11-06
JP2021519610A (ja) 2021-08-12
CN111936514A (zh) 2020-11-13
AR115320A1 (es) 2020-12-23
EP3774885A2 (fr) 2021-02-17
AU2023222983A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
MA52212A (fr) Anticorps multivalent
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
MA52366A (fr) Anticorps anti-tl1a optimisés
EP3883970A4 (fr) Anticorps anti-b7-h3
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47268A (fr) Anticorps anti-gpc3
EP3836960A4 (fr) Anticorps cd47 thérapeutiques
EP3822289A4 (fr) Antibody anti-sirp alpha
MA52742A (fr) Anticorps bispécifiques dll3-cd3
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
EP3498840A4 (fr) Anticorps anti-lag-3
EP3423089A4 (fr) Anticorps anti-tigit
MA49749A (fr) Anticorps anti-cd137
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3617231A4 (fr) Anticorps anti-gpc-1
MA52152A (fr) Anticorps
EP3492591A4 (fr) Anticorps anti-b7-h4
MA51134A (fr) Anticorps anti-alpha-synucléine
IL281717A (en) Antibody formulation
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3752536A4 (fr) Anticorps anti-her2
EP3831851A4 (fr) Anticorps anti-btla